Pancreatic Cancer Study Offers New Treatment Insights
TODAY'S SIGNAL — Three distinct forces are reshaping healthcare this week.
Meanwhile, GLP-1 science is being reexamined at a foundational level — the researchers behind the drugs now suggest targeting GLP-1 may not be necessary for ef…
First, a potential paradigm shift in oncology: Revolution Medicines' daraxonrasib trial data in pancreatic cancer is being called a possible "new era" by leading oncologists, signaling that RAS-targeted therapies may finally crack one of the most intractable cancers. Second, the ACA coverage ecosystem is showing real stress — enrollment declined 17% to 26% in 2026, driven by premium non-payment, which could push uncompensated care costs back onto providers and destabilize ri…
One pattern. Trace it.
- 01
A pattern worth naming
(2) ACA enrollment trajectory — CMS enrollment data for Q2 2026 will reveal whether the Wakely-reported decline is stabilizing or accelerating; watch for state-level responses such as enhanced subsidies or outreach. (3) State AI legislation wave — at least a dozen states are considering AI regulation in healthcare; watch for bills in California, New York, and Illinois that could establish de facto national standards.
“If ACA enrollment keeps dropping and uninsured volume climbs 20%, do our current charity care policies bankrupt us or just erode margin?”
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →